India markets closed
  • BSE SENSEX

    49,591.32
    -154.89 (-0.31%)
     
  • Nifty 50

    14,834.85
    -38.95 (-0.26%)
     
  • USD/INR

    74.7100
    +0.1490 (+0.20%)
     
  • Dow

    33,800.60
    +297.03 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.88 (+0.51%)
     
  • BTC-INR

    4,459,008.50
    +89,608.50 (+2.05%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • Hang Seng

    28,698.80
    -309.27 (-1.07%)
     
  • Nikkei

    29,768.06
    +59.08 (+0.20%)
     
  • EUR/INR

    88.9028
    +0.0430 (+0.05%)
     
  • GBP/INR

    102.3868
    -0.0108 (-0.01%)
     
  • AED/INR

    20.2940
    +0.0390 (+0.19%)
     
  • INR/JPY

    1.4647
    +0.0019 (+0.13%)
     
  • SGD/INR

    55.7130
    +0.0690 (+0.12%)
     

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

Cullinan Management, Inc.
·1-min read

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00am EST
Location: Virtual

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7am EST on Tuesday, March 9th, 2021, for registered attendees only.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 716.725.5019
jtrigilio@cullinanoncology.com